JP2015506352A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015506352A5 JP2015506352A5 JP2014549212A JP2014549212A JP2015506352A5 JP 2015506352 A5 JP2015506352 A5 JP 2015506352A5 JP 2014549212 A JP2014549212 A JP 2014549212A JP 2014549212 A JP2014549212 A JP 2014549212A JP 2015506352 A5 JP2015506352 A5 JP 2015506352A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical formulation
- formulation according
- treatment
- antagonist
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 13
- 239000005557 antagonist Substances 0.000 claims 6
- 230000033115 angiogenesis Effects 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 108010017642 Integrin alpha2beta1 Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 230000017066 negative regulation of growth Effects 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/374,369 US8946159B2 (en) | 2011-12-22 | 2011-12-22 | Administration of an antagonist of α5β1 for anti-angiogenesis and cancer treatment |
| US13/374,369 | 2011-12-22 | ||
| PCT/US2012/070399 WO2013096335A1 (en) | 2011-12-22 | 2012-12-18 | Administration of an antagonist of alpha 5 beta 1 for anti-antiogenesis and cancer treatment |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015506352A JP2015506352A (ja) | 2015-03-02 |
| JP2015506352A5 true JP2015506352A5 (cg-RX-API-DMAC7.html) | 2016-05-19 |
| JP6224615B2 JP6224615B2 (ja) | 2017-11-01 |
Family
ID=48655153
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014549212A Active JP6224615B2 (ja) | 2011-12-22 | 2012-12-18 | 抗血管新生およびがん処置のためのα５β１のアンタゴニストの投与 |
Country Status (5)
| Country | Link |
|---|---|
| US (6) | US8946159B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2793924B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP6224615B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN104159596B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013096335A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110319335A1 (en) | 2010-06-23 | 2011-12-29 | Xiaodong Feng | Combined administration of integrin receptor antagonists for anti-angiogenic therapy |
| US8946159B2 (en) | 2011-12-22 | 2015-02-03 | California Northstate College Of Pharmacy, Llc | Administration of an antagonist of α5β1 for anti-angiogenesis and cancer treatment |
| WO2016029131A1 (en) * | 2014-08-22 | 2016-02-25 | National Cheng Kung University | Disintegrin variants and pharmaceutical uses thereof |
| AU2019234836A1 (en) * | 2018-03-13 | 2020-09-17 | The Regents Of The University Of California | Inhibitors of integrin alpha 2 beta 1 and methods of use |
| CN115916176A (zh) | 2020-05-01 | 2023-04-04 | 加利福尼亚大学董事会 | α2β1整联蛋白的抑制剂和其使用方法 |
| WO2022178218A1 (en) | 2021-02-19 | 2022-08-25 | Mevion Medical Systems, Inc. | Gantry for a particle therapy system |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU3734693A (en) | 1992-03-17 | 1993-10-21 | Board Of Regents, The University Of Texas System | Neurotrophic peptides |
| JP2002514605A (ja) * | 1998-05-08 | 2002-05-21 | ザ レジェンツ オブ ザ ユニヴァースティ オブ カリフォルニア | 血管形成を検出および阻害する方法 |
| US6852318B1 (en) * | 1998-05-08 | 2005-02-08 | The Regents Of The University Of California | Methods for detecting and inhibiting angiogenesis |
| CA2400040A1 (en) * | 2000-02-25 | 2001-08-30 | Immunex Corporation | Integrin antagonists |
| US20040121031A1 (en) | 2002-12-09 | 2004-06-24 | Muhammed Majeed | Novel topical skin care and nutraceutical applications of Glabridin or extracts containing a defined amount (4-90%) of Glabridin |
| US7101707B2 (en) | 2002-12-23 | 2006-09-05 | Cedars-Sinai Medical Center | Secondary sprouting for isolation and expansion of endothelial sprout cells and endothelial precursor cells from a mixed population and for screening substances |
| UA88294C2 (ru) * | 2004-03-24 | 2009-10-12 | Фейсит Биотек Корпорейшен | ПРИМЕНЕНИЕ АНТИ-α5β1 АНТИТЕЛ ДЛЯ УГНЕТЕНИЯ ПРОЛИФЕРАЦИИ РАКОВЫХ КЛЕТОК |
| CA2560508A1 (en) | 2004-03-24 | 2005-10-06 | Pdl Biopharma, Inc. | Use of anti-alpha5beta1 antibodies to inhibit cancer cell proliferation |
| EP1898940A4 (en) * | 2005-06-07 | 2010-05-26 | Univ Pennsylvania | Alpha2beta1 / GPIa IIA INTEGRIN INHIBITORS |
| KR101201886B1 (ko) | 2006-01-19 | 2012-11-15 | 아이진 주식회사 | 펩타이드를 유효성분으로 하는 혈관 관련 질환 치료제 조성물 |
| US20070287664A1 (en) | 2006-03-23 | 2007-12-13 | Schering Corporation | Combinations of HCV protease inhibitor(s) and CYP3A4 inhibitor(s), and methods of treatment related thereto |
| US8008256B2 (en) * | 2006-05-01 | 2011-08-30 | University Of Southern California | Combination therapy for treatment of cancer |
| US20080267978A1 (en) | 2006-08-28 | 2008-10-30 | Mary Zutter | Anti-angiogenic targets for cancer therapy |
| EP2268317B1 (en) | 2008-03-14 | 2020-02-26 | VisEn Medical, Inc. | Integrin targeting agents and in vivo and in vitro imaging methods using the same |
| US20100105644A1 (en) | 2008-10-27 | 2010-04-29 | The Regents Of The University Of Michigan | Botanical composition for enhanced skin repair and uses thereof |
| JP2012510466A (ja) | 2008-12-01 | 2012-05-10 | ライラ ファーマシューティカルズ ピーブイティ．エルティディ． | 炎症、皮膚異常及び粘膜異常並びに他の皮膚疾病及び粘膜疾病の治療のための局部用製剤 |
| US8987493B2 (en) | 2010-05-20 | 2015-03-24 | Temple University—Of the Commonwealth System of Higher Education | Process for synthesis of silane dipeptide analogs |
| US20110311335A1 (en) * | 2010-06-21 | 2011-12-22 | Douglas Wike | Removable fastener |
| US20110319335A1 (en) | 2010-06-23 | 2011-12-29 | Xiaodong Feng | Combined administration of integrin receptor antagonists for anti-angiogenic therapy |
| IL210587A0 (en) | 2011-01-12 | 2011-03-31 | Adel Jamil Hidmi | Natural preparation for treatment of skin sores and lesions |
| US8946159B2 (en) | 2011-12-22 | 2015-02-03 | California Northstate College Of Pharmacy, Llc | Administration of an antagonist of α5β1 for anti-angiogenesis and cancer treatment |
-
2011
- 2011-12-22 US US13/374,369 patent/US8946159B2/en active Active
-
2012
- 2012-11-07 US US13/671,462 patent/US8815805B2/en active Active
- 2012-12-18 EP EP12859266.4A patent/EP2793924B1/en active Active
- 2012-12-18 JP JP2014549212A patent/JP6224615B2/ja active Active
- 2012-12-18 WO PCT/US2012/070399 patent/WO2013096335A1/en not_active Ceased
- 2012-12-18 EP EP20194742.1A patent/EP3777877B1/en active Active
- 2012-12-18 CN CN201280070464.9A patent/CN104159596B/zh active Active
-
2014
- 2014-12-18 US US14/575,266 patent/US10722555B2/en active Active
-
2020
- 2020-06-12 US US16/899,859 patent/US11318184B2/en active Active
-
2022
- 2022-03-25 US US17/704,522 patent/US12053504B2/en active Active
-
2024
- 2024-06-24 US US18/752,340 patent/US20240342240A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ706836A (en) | Methods of treating cancer | |
| JP2015506352A5 (cg-RX-API-DMAC7.html) | ||
| JP2014502638A5 (cg-RX-API-DMAC7.html) | ||
| JP2017505782A5 (cg-RX-API-DMAC7.html) | ||
| MX345928B (es) | Composiciones terapeuticamente activas y metodos de uso de las mismas. | |
| TR201807411T4 (tr) | DNA-PK inhibitörleri. | |
| UA117451C2 (uk) | Терапевтично активні сполуки і способи їх застосування | |
| JP2012255026A5 (cg-RX-API-DMAC7.html) | ||
| JP2010209081A5 (cg-RX-API-DMAC7.html) | ||
| TN2012000335A1 (en) | Antibody formulation and therapeutic regimens | |
| JP2013522184A5 (cg-RX-API-DMAC7.html) | ||
| PL3489261T3 (pl) | Przeciwciała i szczepionki do stosowania w leczeniu nowotworów z ekspresją ROR1 i w hamowaniu przerzutu | |
| JP2016533366A5 (cg-RX-API-DMAC7.html) | ||
| PL3791896T3 (pl) | Terapia skojarzona obejmująca przeciwciała przeciwko klaudynie 18.2 do leczenia nowotworu | |
| PH12016500164B1 (en) | Therapeutically active compounds and their methods of use | |
| JP2015500225A5 (cg-RX-API-DMAC7.html) | ||
| EA201490014A1 (ru) | Модифицированное высвобождение 4-метил-3-[[4-(3-пиридинил)-2-пиримидинил]амино]-n-[5-(4-метил-1h-имидазол-1-ил)-3-(трифторметил)фенил]бензамида, солюбилизированного с использованием органических кислот | |
| JP2016528162A5 (cg-RX-API-DMAC7.html) | ||
| PH12016502354A1 (en) | Pharmaceutical composition | |
| JP2016520528A5 (cg-RX-API-DMAC7.html) | ||
| JP2017519027A5 (cg-RX-API-DMAC7.html) | ||
| MX2018012457A (es) | Terapia combinatoria con inhibidores notch y cdk4/6. | |
| PH12015502616A1 (en) | Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer | |
| EP2682459A4 (en) | ONCOLYTIC ADENOVIRES FOR A TEMPORARY THERAPY AND USE THEREOF | |
| JP2014523398A5 (cg-RX-API-DMAC7.html) |